Filing Details

Accession Number:
0001656472-21-000029
Form Type:
4
Zero Holdings:
No
Publication Time:
2021-03-10 17:34:38
Reporting Period:
2021-03-08
Accepted Time:
2021-03-10 17:34:38
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1656472 Cronos Group Inc. CRON Medicinal Chemicals & Botanical Products (2833) 000000000
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1797199 Ryan Michael Gorenstein 111 Peter Street, Suite 300
Toronto A6 M5V 2H1
Executive Chairman Yes Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Shares Acquisiton 2021-03-08 1,200,000 $0.97 9,632,536 No 4 M Direct
Common Shares Disposition 2021-03-08 410,589 $9.54 9,221,947 No 4 F Direct
Common Shares Disposition 2021-03-09 185,000 $10.00 9,036,947 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Direct
No 4 F Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Shares COMMON SHARE OPTION (right to buy) Disposition 2021-03-08 1,200,000 $0.00 1,200,000 $0.97
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
0 2021-10-06 No 4 M Direct
Footnotes
  1. The price reported was converted from the Canadian exercise price of C$1.23 to U.S. dollars using an exchange rate of C$1.00 to US$0.7887 as reported by Bloomberg as of March 5, 2021.
  2. Cronos Group Inc. (the "Company") withheld 410,589 common shares underlying the options for payment of the exercise price and to cover applicable withholding taxes, using the closing price of the Company's common shares on March 5, 2021 of C$12.09 as reported on the Toronto Stock Exchange.
  3. The price reported is in U.S. dollars based on the exchange rate of C$1.00 to US$0.7887 as reported by Bloomberg as of March 5, 2021.
  4. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $9.90 to $10.07, inclusive. The reporting person undertakes to provide to the Company, any security holder of the Company or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote (4) to this Form 4.
  5. The options were granted October 6, 2016 and vest in monthly installments over a four-year period.